Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment


PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website.

View original post here:
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Related Posts